Izalontamab Brengitecan for carcinoma, transitional cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Mar 2025: Trial registered, NCT06857175
  2. 25 Mar 2025: Trial started, NCT06857175

The trials

NCT06857175: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)

State
Under way
Phase
Phase 3
People
515 taking part
Started
25 Mar 2025
Primary completion
Jun 2027
Arms
BL-B01D1
Results
None posted
  1. 4 Mar 2025: Trial registered
  2. 25 Mar 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.